Benjamin Yudkoff, MD, MA, and Gene Dolgin of Lumin Health discuss where esketamine fits in the treatment-resistant depression algorithm, how to manage safety and treatment continuity in real-world practice, and what it takes to launch and sustain an interventional ketamine and esketamine practice.
In this Psychiatric Times Insights series, learn about key updates and clinical insights related to data presented at the 2026 ASCP Annual Meeting evaluating the safety and efficacy of transitioning patients from atypical antipsychotics to Cobenfy (xanomeline-trospium) using either a 2-week or 4-week cross-titration approach, and the practical guidance clinicians need to confidently make this switch in everyday practice.
John J. Miller, MD, the editor-in-chief of Psychiatric Times, provides insights on treatment practices and the evolving therapeutic landscape for patients with posttraumatic stress disorder (PTSD).
